Related Experiment Video

Updated: Oct 13, 2025

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

7.1K

Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for

Sébastien Morin1, Marc Lallemant2, Anthony Garcia-Prats3,4

  • 1From the Medicines Patent Pool, Geneva, Switzerland.

The Pediatric Infectious Disease Journal
|November 16, 2021
PubMed

Insights

Children can benefit from COVID-19 therapies, even with lower risk. Accelerating pediatric COVID-19 therapeutic research is crucial for optimizing treatment trials and improving outcomes.

Area of Science:

  • Pediatric infectious diseases
  • Clinical pharmacology
  • Global health

Background:

  • Children with COVID-19, while at lower risk than adults, can still experience severe outcomes.
  • Effective therapeutic interventions for pediatric COVID-19 are essential for optimizing clinical management.
  • Understanding disease presentation and prognosis in children is key for advancing treatment strategies.

Purpose of the Study:

  • To highlight the importance of accelerating therapeutic research and development for pediatric COVID-19.
  • To share insights from the Global Accelerator for Paediatric Formulations to guide future efforts.
  • To emphasize the need for collective action in pediatric COVID-19 therapeutic research.

Main Methods:

  • This perspective synthesizes experiences and lessons learned from a global initiative focused on pediatric drug development.
  • It outlines strategies for enhancing collaboration and efficiency in pediatric therapeutic research.
  • The approach emphasizes adapting existing frameworks for the specific needs of pediatric COVID-19 research.

Main Results:

  • The Global Accelerator for Paediatric Formulations provides a model for streamlining pediatric drug development.
  • Collective efforts can significantly accelerate the availability of effective COVID-19 treatments for children.
  • Key challenges and opportunities in pediatric therapeutic research are identified.

Conclusions:

  • Accelerating pediatric COVID-19 therapeutic research is achievable through collaborative and strategic approaches.
  • Optimizing clinical trial design and implementation is vital for pediatric populations.
  • Continued global cooperation is necessary to ensure equitable access to life-saving treatments for children worldwide.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K
A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

6.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
21
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
24
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
31
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
35
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
900